focus -WSS

focus

author：entertainment 2025-09-06 01:58:02 - browse：8299

a liver made up by geometric shapes – biotech coverage from STAT — Adobe

Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion.

Alfasigma, an Italian pharmaceutical firm, will pay $19 a share for Intercept, in a roughly $800 million cash deal that represents an 80% premium to the company’s recent trading price. Intercept expects the deal to close by the end of the year.

The transaction comes three months after the Food and Drug Administration rejected Intercept’s treatment for NASH, an increasingly common fatty liver disease perceived as a potential gold mine by drug companies. Intercept’s medicine, called obeticholic acid, would have been the first approved treatment for NASH, but serious concerns about the risk of drug-related liver damage and uncertainty over whether its modest effects would improve patients’ lives made it unapprovable in the eyes of the FDA.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： How housing is health care on Long Island

WSS

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Millions may soon lose Medicaid when they don't have to

Novo: Oral version of Ozempic leads to 15% weight loss

Biogen nominates mother of director’s child to replace him on board

Biden administration plans revamp of organ transplant system

FDA panel endorses Alnylam’s heart drug — after picking it apart

Wikipedia

focus

knowledge

Psychedelics group wrestles with new pharma identity

Regeneron agrees to White House price limits on anti

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Walmart eyes Medicare Advantage provider ChenMed

Trump demands the U.S. pay no more for drugs than other countries … again

Altering the blood type of lungs raises potential for universal organs for transplants

Medical leaders decry Supreme Court decision on affirmative action

New weight loss drugs vying to be the next Wegovy or Mounjaro

How one medical school became remarkably diverse

Mom launches Girl Scout troop for LGBTQ youth in Texas

focus

Private equity could exacerbate cardiology's overuse problem, experts fear

Bispecific antibodies are next new thing in cancer immunotherapy

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

Novo: Oral version of Ozempic leads to 15% weight loss

Long Covid needs a new name — and a new frame

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Wikipedia

explore

explore

leisure time